Ki 67 expression in 35 borderline ovarian tumours: Relations with clinicopathologic parameters and ploidy

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 76, Issue 2, 1998, Pages 175-180

  Daraï, Emile ^a,b   Walker Combrouze, Francine ^a   Dauge Geoffroy, Marie Christine ^a   Vincent, Yves ^a   Feldmann, Gérard ^b   Madelenat, Patrick ^a   Jean Yves Scoazec, ^b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cytometry; DNA ploidy; Immunohistochemistry; Ki 67; Ovarian tumours

Indexed keywords

CELL NUCLEUS ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOMETRY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; PLOIDY; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032007815     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(97)00169-3     Document Type: Article

References (25)

1. Powell D.E., Puls L., Van Nagell J. Current concepts in epithelial tumours: Does benign to malignant transformation occur? Human Pathol. 23:1992;846-847.
2. Russell P. Borderline epithelial tumours of the ovary: a conceptual dilemma. Clin Obstet Gynecol. 11:1984;259-277.
3. Isola J., Kallioniemi O.P., Korte J.M., Wahlstrom T., Aine R., Helle M., Helin H. Steroid receptors and Ki 67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol. 162:1990;295-301.
4. Huettner P.C., Weinberg D.S., Lage J.M. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol. 141:1992;699-706.
5. Baak J.P., Wisse-Brekelmans E.C., Uyterlinde A.M., Schipper N.W. Evaluation of the prognostic value of morphometric features and cellular DNA content in FIGO I ovarian cancer patients. Anal Quant Cytol Histol. 9:1987;287-290.
6. Berchuck A., Boente M.P., Kerns B.J., Kinney R.B., Soper J.T., Clarke-Pearson D.L., Bast R.C., Bacus S.S. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol. 44:1992;61-65.
7. Kallioniemi O.P., Punnonen R., Mattila J., Lehtinen M., Koivula T. Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer. 61:1988;334-339.
8. Iversen O.-E. Prognostic value of the flow cytometric DNA index in human ovarian carcinoma. Cancer. 61:1988;971-975.
9. Oncology Committee of the International Federation of Gynaecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynaecology and Obstetrics. Am J Obstet Gynecol. 156:1987;263-264.
10. Hart W.R., Norris H.J. Borderline and malignant mucinous tumours of the ovary. Cancer. 31:1973;1031-1045.
11. Henriksen R., Stang P., Backstrom T., Wilander E., Tribukait B., Oberg K. Ki 67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res. 14:1994;603-608.
12. Hedley D., Friedlander M., Taylor I., Rugg C., Musgrove E. Method for analysis of cellular DNA content in paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 4:1983;166-170.
13. Harris R., Whittemore A.S., Itnyre J. The collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol. 136:1992;1204-1211.
14. Darai E., Teboul J., Walker F., Benifla J.L., Meneux E., Guglielmina J.N., Pennehouat G., Renolleau C., Sebban E., Madelenat P. Epithelial ovarian carcinoma of low malignant potential. Eur J Obstet Gynecol. 66:1996;141-145.
15. Kliman L., Rome R.M., Fortune D.W. Low malignant potential tumours of the ovary: a study of 76 cases. Obstet Gynecol. 68:1986;338-344.
16. Gerdes J., Schwab U., Lemke H., Stein H. Production of mouse monoclonal antibody reacting with a human nuclear antigen associated with proliferation. Int J Cancer. 31:1983;13-20.
17. Kerns B.J., Jordan P.A., Faerman L.L., Berchuck A., Bast R.C. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 101:1994;192-197.
18. Klemi P.J., Joensuu H., Kiilholma P., Maenpaa J. Clinical significance of abnormal nuclear DNA content in serous ovarian tumours. Cancer. 62:1988;2005-2010.
19. Lage J.M., Weinberg D.S., Huettner P.C., Mark S.D. Flow cytometric analysis of nuclear DNA content in ovarian tumours. Cancer. 69:1992;2668-2675.
20. Guerrieri C., Hogberg T., Wingern S., Fristedt S., Simonsen E., Boeryd B. Mucinous borderline and malignant tumours of the ovary. Cancer. 74:1994;2329-2340.
21. Seidman J.D., Norris H.J., Griffin J.L., Hitchcock C.L. DNA flow cytometric analysis of serous ovarian tumours of low malignant potential. Cancer. 71:1993;3947-3951.
22. Kaern J., Trope C.G., Kristensen G.B., Abeler V.M., Pettersen E.O. DNA ploidy, the most important prognostic factor in patients with borderline tumours of the ovary. Int J Gynecol Cancer. xx:1993;xx-xx.
23. Harlow B.L., Furh J.E., McDonald T.W., Schwartz S.M., Beuerlein F.J., Weiss N.S. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumours. Gynecol Oncol. 50:1993;305-309.
24. Lai C.H., Hsueh S., Chang T.C., Tseng C.J., Huang K.G., Chou H.H., Chen S.M. The role of DNA flow cytometry in borderline malignant ovarian tumours. Cancer. 78:1996;794-802.
25. Padberg B.C., Arps H., Franke U., Thiedemann C., Rehpenning W., Stegner H.E., Lietz H., Schroder S., Dietel M. DNA cytophotometry and prognosis in ovarian tumours of borderline malignancy. A clinicomorphological study of 80 cases. Cancer. 69:1992;2510-2514.